secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2023-02-17T23:59:59+00:00
Accession:  0001438533-23-000002
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants accelerated approval to Travere's FILSPARI for IgA nephropathy
-------------------------------------------------------------------------

- FDA approved FILSPARI (sparsentan) to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid progression; continued approval contingent on confirmatory data.
- FILSPARI showed 45% mean reduction in proteinuria vs 15% for irbesartan in post-hoc sensitivity analysis (label data).
- Travere expects to pay $23M milestone to Ligand and BMS in Q1 2023 due to approval.
- Topline confirmatory endpoint results from PROTECT Study expected Q4 2023; DUPLEX FSGS results expected Q2 2023.
- FILSPARI to be available week of Feb 27, 2023; estimated addressable US patients 30,000-50,000.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853323000002/0001438533-23-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853323000002/tvtx-20230217.htm
  HTML page:      https://secwatch.observer/filing/0001438533-23-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer